Articles related to DEPRESSION

In this meta-analysis including 340 patients across six clinical trials, ECT was more effective than ketamine in treating depression. There were no identified differences between the groups in terms of cognition, memory, or serious adverse events.

Although results of meta-analyses on the link between vitamin D and depression have historically been mixed, emerging research suggests vitamin D supplementation may help with depression in certain populations. For example, revisiting prior meta analyses, investigators have found that vitamin D supplementation decreased depressive symptoms in MDD patients, as well as in women with perinatal depressive symptoms.

In this study involving 452 patients with diagnoses of MDD, GAD, and PTSD, IM ketamine reduced depression by 38% and anxiety by 50%, with persistence over 7 months of maintenance therapy.

To test whether low doses of the NMDA-receptor partial-agonist D-cycloserine would enhance intermittent TBS (iTBS) treatment outcomes in MDD, this single-site 4-week, double-blind, placebo-controlled, randomized clinical trial compared TBS with D-cycloserine vs. TBS with placebo. The TBS plus D-cycloserine group had greater improvements in MADRS scores compared with the iTBS plus placebo group, with a mean difference of −6.15.

Data from the open label Evaluation of NMDA Modulation for Depressive Episodes (EVOLVE) study presented at Psych Congress 2022 showed a significant decrease in HAM-A scores at 1 week, with further decreases in scores observed through 12 months.

In treatment-resistant depression, two studies found that COMP360 psilocybin therapy reduced depression and one study reported that using precision medicine for ketamine dosing might decrease the high efficacy-low effectiveness gap.